Supernus Pharmaceuticals Analyst Ratings
Supernus Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/25/2023 | 79.72% | Piper Sandler | $43 → $42 | Maintains | Overweight |
| 05/10/2023 | 96.83% | Piper Sandler | $45 → $46 | Maintains | Overweight |
| 01/23/2023 | 101.11% | Piper Sandler | $40 → $47 | Maintains | Overweight |
| 08/31/2022 | 62.6% | Piper Sandler | $33 → $38 | Maintains | Overweight |
| 04/13/2021 | 71.16% | Jefferies | $25 → $40 | Upgrades | Hold → Buy |
| 06/16/2020 | 32.65% | Piper Sandler | $25 → $31 | Upgrades | Neutral → Overweight |
| 06/15/2020 | 2.7% | Jefferies | → $24 | Reinstates | → Hold |
| 04/16/2020 | 2.7% | Stifel | $25 → $24 | Maintains | Hold |
| 11/07/2019 | -1.58% | Stifel | $55 → $23 | Downgrades | Buy → Hold |
| 11/06/2019 | — | Jefferies | Downgrades | Buy → Hold | |
| 12/17/2018 | 169.58% | Mizuho | $61 → $63 | Maintains | Buy |
| 11/12/2018 | 178.13% | B. Riley Securities | $68 → $65 | Maintains | Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年10月25日 | 79.72% | 派珀·桑德勒 | $43→$42 | 維護 | 超重 |
| 2023年05月10日 | 96.83% | 派珀·桑德勒 | $45→$46 | 維護 | 超重 |
| 2023年1月23日 | 101.11% | 派珀·桑德勒 | $40→$47 | 維護 | 超重 |
| 2022年08月31日 | 62.6% | 派珀·桑德勒 | $33→$38 | 維護 | 超重 |
| 04/13/2021 | 71.16% | 傑富瑞 | $25→$40 | 升級 | 持有→購買 |
| 06/16/2020 | 32.65% | 派珀·桑德勒 | $25→$31 | 升級 | 中性→超重 |
| 2020/06/15 | 2.7% | 傑富瑞 | →$24 | 恢復 | →保留 |
| 04/16/2020 | 2.7% | Stifel | $25→$24 | 維護 | 保持 |
| 2019/07/11 | -1.58% | Stifel | $55→$23 | 評級下調 | 購買→Hold |
| 2019/06/11 | - | 傑富瑞 | 評級下調 | 購買→Hold | |
| 2018年12月17日 | 169.58% | 瑞穗 | $61→$63 | 維護 | 買 |
| 2018年11月12日 | 178.13% | B.萊利證券 | $68→$65 | 維護 | 買 |
What is the target price for Supernus Pharmaceuticals (SUPN)?
Supernus PharmPharmticals(SUPN)的目標價是多少？
The latest price target for Supernus Pharmaceuticals (NASDAQ: SUPN) was reported by Piper Sandler on October 25, 2023. The analyst firm set a price target for $42.00 expecting SUPN to rise to within 12 months (a possible 79.72% upside). 3 analyst firms have reported ratings in the last year.
派珀·桑德勒於2023年10月25日報道了Supernus製藥公司(納斯達克代碼：SUPN)的最新目標價。這家分析公司將目標價定為42.00美元，預計SUPN將在12個月內上漲(可能上漲79.72%)。3家分析公司在過去一年公佈了評級。
What is the most recent analyst rating for Supernus Pharmaceuticals (SUPN)?
Supernus PharmPharmticals(SUPN)的最新分析師評級是多少？
The latest analyst rating for Supernus Pharmaceuticals (NASDAQ: SUPN) was provided by Piper Sandler, and Supernus Pharmaceuticals maintained their overweight rating.
分析師對Supernus PharmPharmticals(納斯達克代碼：SUPN)的最新評級由Piper Sandler提供，Supernus PharmPharmticals維持其增持評級。
When is the next analyst rating going to be posted or updated for Supernus Pharmaceuticals (SUPN)?
Supernus PharmPharmticals(SUPN)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Supernus Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Supernus Pharmaceuticals was filed on October 25, 2023 so you should expect the next rating to be made available sometime around October 25, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Supernus製藥公司的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Supernus製藥的上一次評級是在2023年10月25日提交的，所以你應該預計下一次評級將在2024年10月25日左右的某個時候公佈。
Is the Analyst Rating Supernus Pharmaceuticals (SUPN) correct?
分析師對Supernus PharmPharmticals(SUPN)的評級正確嗎？
While ratings are subjective and will change, the latest Supernus Pharmaceuticals (SUPN) rating was a maintained with a price target of $43.00 to $42.00. The current price Supernus Pharmaceuticals (SUPN) is trading at is $23.37, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Supernus製藥(SUPN)評級維持不變，目標價在43.00美元至42.00美元之間。Supernus製藥(SUPN)目前的交易價格為23.37美元，超出了分析師的預測區間。